CONCORD Pharmaceuticals Ltd.

What CONCORD Pharmaceuticals Ltd. does

CONCORD Pharmaceuticals Ltd. is a Bangladesh-based pharmaceutical manufacturer founded in 2010 and operating as a sister concern of the NOAPARA GROUP diversified conglomerate. The company manufactures human medicines — tablets, capsules, oral liquids/syrups, suspensions, and injectable products — across a portfolio of 112 dosage forms spanning antibiotics, antivirals, antidiabetics, anti-ulcerants, analgesics, cardiovascular drugs, vitamins and minerals, and NSAIDs. Notable products include Dapazin (Dapagliflozin), the first SGLT2 inhibitor launched in Bangladesh, and Relikof, both first-time-in-country introductions. Manufacturing occurs at a WHO cGMP-certified facility in Kanchpur, Narayanganj, supported by in-house R&D, Quality Control, and temperature-controlled warehouse operations.

The company operates a dual distribution model. Domestically, 11 depot locations cover all divisions of Bangladesh, with Medical Promotion Officers, Area Managers, and Regional Sales Managers selling into hospitals, retailers, clinics, and pharmacies. Internationally, finished pharmaceutical products are exported to 10–14 destinations — Bhutan, Cambodia, Myanmar, Sri Lanka, Vietnam, Thailand, Liberia, Yemen, Afghanistan, and Congo — typically through in-country agents and distributors (e.g., Cambodian Cooperation Pharma Ltd.). Revenue is generated through one-time product sales across both channels; no subscription, recurring, or disclosed pricing model exists. The company holds WHO cGMP, ISO 9001:2015, Yemen GMP, and Cambodia Ministry of Health accreditations.

Beyond core generics, CONCORD has expanded into adjacent healthcare verticals through the jointly controlled Health Associates vehicle: EW Villa Medica (regenerative medicine and medical tourism in partnership with a German group), DMFR Molecular Lab (BSL-3 diagnostics), and TotiCell (stem cell and regenerative therapy). A tele-medicine platform extends the company's consumer-facing footprint. The company is privately held, does not publicly disclose revenue, and employs 71 people.

Name

CONCORD Pharmaceuticals Ltd.

Legal name

CONCORD Pharmaceuticals Ltd.

Website

https://concordpharma-bd.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

CONCORD Pharmaceuticals Ltd. is a Bangladesh-based WHO-GMP certified manufacturer of generic human medicines across 112 dosage forms, distributing domestically through 11 depots and exporting to 10+ countries, with adjacent regenerative medicine and diagnostics ventures.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Oral solid dosage
• Injectable formulations
• Generic medicines

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Domestic): Manufacturing and selling pharmaceutical products across Bangladesh through nationwide distribution network covering hospitals, retailers, clinics, and pharmacies
2. International Exports: Exporting pharmaceutical products to 10+ international destinations including Bhutan, Cambodia, Myanmar, Sri Lanka, Vietnam, Thailand, Liberia, Yemen, Afghanistan, and Congo. Export journey started in 2015.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

CONCORD Pharmaceuticals Ltd. manufactures and markets generic human medicines in multiple dosage forms — tablets, capsules, syrups, suspensions, and injectable products — across therapeutic classes such as Antibiotics, Antivirals, Antidiabetics, Anti-Ulcerants, Analgesics, Antihistamines, Cardiovascular, Vitamins & Minerals, and NSAIDs. The portfolio includes 112 dosage forms, with notable first-time launches in Bangladesh such as Dapazin (Dapagliflozin, the country's first SGLT2 inhibitor) and Relikof cough syrups. Products are manufactured at a WHO cGMP-certified plant in Narayanganj, distributed domestically through 11 depots, and exported to 10+ international destinations.

Product overview

CONCORD Pharmaceuticals Ltd. is a pharmaceutical manufacturer producing human medicines including tablets, capsules, oral liquids/syrups, suspensions, and injectable products. The company operates as a single unified product portfolio across multiple therapeutic classes including NSAIDs (Acedol Tablet), Cardiovascular (Acubis 2.5 Tablet), Anti-diabetics (Dapazin 5/10 Tablet - first SGLT2 inhibitor in Bangladesh), Gastroprokinetics (Dopagut), Vitamins/Minerals (Conzi Syrup), and Anti-histamines (Unilor 5 mg Tablet). The product portfolio includes 112 dosage forms across therapeutic categories such as Antibiotics, Antivirals, Antidiabetics, Anti-Ulcerants, Analgesics, Cardiovascular drugs, Vitamins & minerals, and NSAIDs. The company is WHO GMP certified and exports to 10+ international destinations including Bhutan, Cambodia, Myanmar, Sri Lanka, Vietnam, Thailand, Liberia, Yemen, Afghanistan, and Congo.

Differentiator

Problem solved

Functional benefit

Brands

• EW Villa Medica: Premium medical tourism destination and wellness clinic offering regenerative medicine, cell therapies, and holistic treatments.
• DMFR Molecular Lab
• TotiCell

Products and services

• Acedol Tablet NSAID tablet containing Aceclofenac 100 mg, used as an anti-inflammatory pain reliever for patients requiring NSAID therapy.
• Acubis 2.5 Tablet Cardiovascular tablet containing Bisoprolol 2.5 mg, prescribed for hypertension and heart-related conditions.
• Conzi Syrup Vitamin and mineral supplement syrup containing Zinc 10 mg/5 ml for patients with zinc deficiency or as a dietary supplement.
• Dopagut Suspension Gastroprokinetic oral suspension for the treatment of gastrointestinal motility disorders.
• Unilor 5 mg Tablet Anti-histamine tablet for the treatment of allergic conditions.
• Holicef 1gm IM Injection Intramuscular injection containing 1 gm of active ingredient for systemic antibacterial treatment.
• Holicef 500mg IV Injection Intravenous injection containing 500 mg of active ingredient for systemic antibacterial treatment.
• Maxdol 30 Injection Injectable analgesic formulation at 30 mg dosage strength for pain management.
• Maxdol 60 Injection Injectable analgesic formulation at 60 mg dosage strength for pain management.
• Brocast 10 Tablet Tablet formulation containing 10 mg of active ingredient.
• Dapazin 5 Tablet Anti-diabetic tablet containing Dapagliflozin INN 5 mg, the first SGLT2 inhibitor launched in Bangladesh for Type 2 diabetes treatment.
• Dapazin 10 Tablet Anti-diabetic tablet containing Dapagliflozin INN 10 mg for Type 2 diabetes treatment.
• Relikof 2.5 Syrup Cough syrup containing Citric Acid Monohydrate BP 31.25 mg/5 ml, first time launched in Bangladesh.
• Relikof Kidz Syrup Pediatric cough syrup at 125 mg/5 ml dosage, first time launched in Bangladesh.

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• EW Villa MedicacoreStrategic or Co-development Partner · 1 January 2018A German regenerative medicine center joint venture project with Concord Pharmaceuticals/Noapara Group. EW Villa Medica integrates Advanced Cell Therapy (VILLA MEDICA) and EUROPEAN WELLNESS to offer premium medical tourism destination services including regenerative medicine, cell therapies, and biomedical diagnostic services in Dhaka, Bangladesh.
• Cambodian Cooperation Pharma LtdcoreChannel Partner/ Reseller/ Distributor · 25 August 2017Partnership for launching Dapazin (Dapagliflozin) in Cambodia. Concord Pharmaceuticals collaborated with Cambodian Cooperation Pharma Ltd to successfully launch Dapazin for the first time in the Cambodian market.
• DMFR Molecular LabminorStrategic or Co-development PartnerWorld-class diagnostic healthcare facility in Bangladesh, established as a Health Associate of Concord Pharmaceuticals. DMFR has introduced Bio-Safety Level-3 (BSL-3) molecular lab for the first time in Bangladesh's private sector, offering accurate, detailed diagnostic testing at international quality standards.
• TotiCell (Advanced Regenerative Healthcare Centre)minorStrategic or Co-development PartnerWorld-class regenerative healthcare center in Dhaka operating as a Health Associate. TotiCell offers regenerative medicine therapies including PRP, stromal vascular fraction (SVF), and stem cell treatments for musculoskeletal conditions, anti-aging, sexual health, and aesthetic procedures using GMP facility-compliant therapeutics.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Incepta Pharmaceuticals Ltd. Bangladesh-based generic manufacturer with one of the broadest product portfolios in the country, strong R&D, and growing exports. Comparable to Concord across solid orals, injectables, and first-to-market launches in Bangladesh.
• Aristopharma Ltd. Bangladesh-based generics manufacturer focused on tablets, capsules, injectables, and topical formulations with growing export presence. Comparable in product format mix, GMP manufacturing standards, and emerging-market exports.
• Beximco Pharmaceuticals Ltd. Leading Bangladeshi generics manufacturer with a broad therapeutic portfolio across antibiotics, cardiovascular, and anti-diabetics, plus a sizable export business. Directly comparable to Concord on product mix, GMP manufacturing, and emerging-market export focus.
• Square Pharmaceuticals Ltd. Bangladesh's largest pharmaceutical manufacturer, producing tablets, capsules, syrups, injectables, and exporting to over 50 countries. Most directly comparable peer: same product format mix, domestic distribution strength, and generic-first strategy as Concord.
• Eskayef Pharmaceuticals Ltd. Bangladesh generics manufacturer (part of Transcom Group) producing tablets, capsules, injectables, and biologics with significant exports. Comparable on WHO-GMP manufacturing, export footprint, and chronic-disease portfolio including diabetes.
• Renata Limited (PLC): Bangladesh-based pharmaceutical manufacturer with animal health and consumer health adjacencies; produces generics across cardiovascular, endocrine, and anti-infectives. Comparable in therapeutic breadth, domestic distribution, and export orientation.
• Healthcare Pharmaceuticals Ltd. Bangladesh pharmaceutical manufacturer producing generics across anti-infectives, cardiovascular, and metabolic therapy with a strong domestic sales force. Comparable in therapeutic portfolio and domestic distribution model.

Broad incumbents

• ACI Limited: Diversified Bangladeshi conglomerate with a sizable pharma division plus consumer goods, agribusiness, and logistics. Comparable manufacturing and distribution footprint to Concord but at much larger scale across multiple business verticals.

Emerging players

• Drug International Limited: Smaller Bangladesh generics manufacturer with a portfolio of tablets, capsules, injectables, and ophthalmics. Comparable to Concord in size tier and emerging-export orientation, though less international footprint.

Regional players

• Beacon Pharmaceuticals Ltd. Bangladesh-based oncology and specialty pharmaceutical manufacturer with growing emerging-market exports. Comparable on WHO-GMP manufacturing and South/Southeast Asian export focus, though more concentrated in specialty/oncology versus Concord's primary-care breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/concord-pharmaceauticals-ltd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CONCORD Pharmaceuticals Ltd.